Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)



As previously announced, William P. Burke will retire from Haemonetics
Corporation (the "Company") on June 30, 2022. Mr. Burke will step down as Chief
Financial Officer and principal financial officer of the Company on April 11,
2022 in connection with James C. D'Arecca's appointment as the Company's new
Chief Financial Officer (as discussed below). Mr. Burke will assist the
Company's Chief Executive Officer and Mr. D'Arecca in the transition until Mr.
Burke's retirement from the Company.

(c), (e)



On March 21, 2022, the Company announced the appointment of James C. D'Arecca as
its Chief Financial Officer, effective April 11, 2022. Mr. D'Arecca will serve
as the Company's principal financial officer and oversee the treasury,
controllership and accounting, investor relations, tax, information technology
and financial planning and analysis functions.

Mr. D'Arecca, 51, joins the Company directly from TherapeuticsMD, Inc., where he
has served as Chief Financial Officer since June 2020. Prior to joining
TherapeuticsMD, Mr. D'Arecca served as the Senior Vice President and Chief
Accounting Officer of Allergen plc (formerly known as Actavis plc) from August
2013 until its merger with AbbVie Inc. in May 2020. Mr. D'Arecca served as Chief
Accounting Officer at Bausch & Lomb prior to joining Actavis plc and earlier in
his career held finance and business development positions of increasing
responsibility at Merck & Co., Inc. and Schering-Plough Corporation. Mr.
D'Arecca began his career with PricewaterhouseCoopers LLP from 1992 to 2005,
where he had an industry focus on pharmaceuticals, medical devices, and consumer
products. Mr. D'Arecca earned a Bachelor of Science in Accounting from Rutgers
University and a Master of Business Administration from Columbia University. He
is a Certified Public Accountant.

Mr. D'Arecca will receive an annual base salary of $525,000 and participate in
the Company's annual short-term incentive compensation program for fiscal 2023,
with a target bonus equal to 75% of his base salary based on the Company's
achievement of select fiscal 2023 financial metrics and his individual
performance, as well as the Company's annual long-term incentive compensation
program for fiscal 2023, with an equity compensation award target value of
$1,100,000, subject to Compensation Committee approval. Mr. D'Arecca will also
receive a $400,000 sign-on bonus after his first 60 days of employment, with
$350,000 repayable in the first 12 months of Mr. D'Arecca's employment upon his
voluntary termination or termination by the Company for cause and $175,000
repayable between the 12th and 24th month of Mr. D'Arecca's employment upon his
voluntary termination or termination by the Company for cause.

Subject to Compensation Committee approval, Mr. D'Arecca will receive an initial
equity grant valued at $600,000 consisting of 50% restricted stock units and 50%
non-qualified stock options that will each vest in annual increments of 25%
beginning on the first anniversary of the date of grant. The exact number of
restricted stock units issued and the strike price of the stock options will be
based upon the closing price of the Company's common stock on the grant date,
and the exact number of stock options issued will be determined using the
applicable Black-Scholes value. The awards will be subject to the terms of the
Company's 2019 Long-Term Incentive Compensation Plan and corresponding forms of
restricted stock unit and stock option award agreements for employees, copies of
which are incorporated by reference into the Company's Form 10-K for the fiscal
year ended April 3, 2021.

Mr. D'Arecca will also enter into the Company's standard forms of executive
severance agreement, change in control agreement and indemnification agreement,
copies of which are incorporated by reference into the Company's Form 10-K for
the fiscal year ended April 3, 2021. The terms of such executive severance and
change in control agreements are described in the "Severance and Change in
Control Agreements with Named Executive Officers" section of the Company's 2021
proxy statement. Mr. D'Arecca will participate in all other elements of the
Company's employee benefit plans for the Company's senior executives as outlined
in the Company's 2021 Proxy Statement.

--------------------------------------------------------------------------------

Item 7.01. Regulation FD Disclosure.

On March 21, 2022, the Company issued a press release relating to the matters described above in Item 5.02. A copy of the press release is furnished as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit Number                Description
  99.1                        Press release of Haemonetics Corporation

dated March 21, 2022 announcing the


                              appointment of James C. D'Arecca as Chief

Financial Officer.



104                           Cover Page Interactive Data File (embedded

within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses